Bayesian meta‐analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations

Abstract

AbstractDuring drug development, evidence can emerge to suggest a treatment is more effective in a specific patient subgroup. Whilst early trials may be conducted in biomarker‐mixed populations, later trials are more likely to enroll biomarker‐positive patients alone, thus leading to trials of the same treatment investigated in different populations. When conducting a meta‐analysis, a conservative approach would be to combine only trials conducted in the biomarker‐positive subgroup. However, this discards potentially useful information on treatment effects in the biomarker‐positive subgroup concealed within observed treatment effects in biomarker‐mixed populations. We extend standard random‐effects meta‐analysis to combine treatment effects obtained from trials with different populations to estimate pooled treatment effects in a biomarker subgroup of interest. The model assumes a systematic difference in treatment effects between biomarker‐positive and biomarker‐negative subgroups, which is estimated from trials which report either or both treatment effects. The systematic difference and proportion of biomarker‐negative patients in biomarker‐mixed studies are used to interpolate treatment effects in the biomarker‐positive subgroup from observed treatment effects in the biomarker‐mixed population. The developed methods are applied to an illustrative example in metastatic colorectal cancer and evaluated in a simulation study. In the example, the developed method improved precision of the pooled treatment effect estimate compared with standard random‐effects meta‐analysis of trials investigating only biomarker‐positive patients. The simulation study confirmed that when the systematic difference in treatment effects between biomarker subgroups is not very large, the developed method can improve precision of estimation of pooled treatment effects while maintaining low bias.